Ftse Mib
33.494,83
0,60%
DAX
19.322,59
0,91%
S&P 500
5.969,34
0,35%
NASDAQ
19.003,65
0,16%
Bitcoin
97.891,00
0,02%
Pepperstone
Advertisement
Registration Strip Icon for discussion Registrati per interagire nei nostri forum attivi per discutere con investitori con idee simili.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ UroGen Pharma Ltd (URGN) UroGen Pharma Ltd (URGN) Notizie

UroGen Pharma Ltd

URGN
11,91
0,36 (3,12%)
23 Nov 2024 - Chiuso
Dati in Delay di 15 minuti
Borsa: NASDAQ
Tipo: Azione
Valuta: USD

Ultime notizie

Data Ora Fonte Titolo
18/11/202412:16EDGAR2Form SC 13D/A - General Statement of Acquisition of..
06/11/202414:04EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
06/11/202414:01EDGAR2Form 8-K - Current report
06/11/202414:00BWUroGen Pharma Reports 2024 Third Quarter Financial Results..
05/11/202414:00BWUroGen Pharma to Present at the Guggenheim Securities..
30/10/202413:00BWUroGen Pharma to Report Third Quarter Financial Results on..
28/10/202413:00BWENVISION Trial Results Published in the Journal of Urology..
15/10/202422:30BWUroGen Announces FDA Acceptance of its New Drug Application..
09/10/202422:22EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/10/202422:21EDGAR2Form 3 - Initial statement of beneficial ownership of..
09/10/202414:18EDGAR2Form 8-K - Current report
09/10/202414:00BWUroGen Appoints Chris Degnan as Chief Financial Officer
02/10/202414:00BWFirst Patient Dosed in Phase 3 Clinical Trial of UGN-103, a..
24/9/202422:15EDGAR2Form 8-K - Current report
16/9/202414:00BWUroGen Receives New U.S. Patent Allowance for..
13/9/202422:15EDGAR2Form 8-K - Current report
12/9/202419:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202419:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
12/9/202419:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/9/202413:16EDGAR2Form 144 - Report of proposed sale of securities
05/9/202414:00BWUroGen Pharma Announces Inducement Grants Under Nasdaq..
29/8/202414:00BWUroGen Pharma to Present at Upcoming Investor Conferences
15/8/202414:00EDGAR2Form 8-K - Current report
14/8/202414:00BWUroGen Submits Completed UGN-102 NDA Seeking Approval as the..
13/8/202414:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/8/202414:01EDGAR2Form 8-K - Current report
13/8/202414:00BWUroGen Pharma Ahead of Schedule to Complete UGN-102 NDA..
08/8/202422:30EDGAR2Form 8-K - Current report
08/8/202415:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202415:09EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202415:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08/8/202415:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05/8/202414:00BWUroGen Pharma to Report Second Quarter 2024 Financial..
09/7/202423:30EDGAR2Form ARS - Annual Report to Security Holders
18/6/202423:07EDGAR2Form 8-K - Current report
18/6/202423:05EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
18/6/202404:51BWUroGen Pharma Announces Pricing of Public Offering of..
17/6/202422:46GLOBEUroGen Pharma Announces Commencement of Public Offering of..
17/6/202422:19EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
13/6/202416:51EDGAR2Form 8-K - Current report
13/6/202416:45BWUroGen Announces Unprecedented 82.3% Duration of Response at..
11/6/202419:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/6/202412:16EDGAR2Form 144 - Report of proposed sale of securities
07/6/202414:00BWUroGen Pharma Announces Inducement Grants Under Nasdaq..
06/6/202414:00BWUroGen Pharma to Host UGN-102 Virtual Data Event on June 13,..
05/6/202414:00BWUroGen Pharma to Present at the 45th Annual Goldman Sachs..
03/6/202414:00BWUroGen Pharma Appoints David Lin as New Chief Commercial..
22/5/202414:00BWUroGen Pharma to Present at the TD Cowen 5th Annual Oncology..
13/5/202414:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13/5/202414:01EDGAR2Form 8-K - Current report
Apertura: 11,60 Min: 11,50 Max: 12,04
Chiusura: 11,55

La tua Cronologia

NASDAQ
URGN
UroGen Pharma
NASDAQ
EEEE
Educate
LSE
QI52
Morg.st.b.v 24
Delayed Upgrade Clock

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network